Crispr Therapeutics shares tumble after significant earnings miss
Investing.com -- Singapore-based Sembcorp Industries Ltd. is currently undertaking a strategic review of its business operations, according to Bloomberg News.
The company, supported by state-owned entity Temasek Holdings Pte, is contemplating various options, which could potentially include going private or selling off some of its assets.
The company is working alongside a financial adviser on this review, the report added. A representative for Sembcorp communicated that the company consistently evaluates options to boost shareholder value. This includes possible investments, divestments, restructuring, listings, and capital management strategies.
“As part of such assessments, we work with consultants from time to time, as the needs arise,” the spokesperson told Bloomberg.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.